TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized Controlled Trial

Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.

Study Overview

• Status: Not yet recruiting
• Conditions: Prostatitis
• Intervention / Treatment: Device: TECAR therapy; Device: Sham TECAR therapy

Detailed Description

Sixty men with chronic prostatitis/chronic pelvic pain will be sourced from the urology outpatient clinic at Tanta University hospitals in Egypt, with referrals from urologists. Patients will be randomly assigned into two groups.

Study group: It will include 30 men receiving true TECAR therapy plus dietary and life style adjustments.

Control group: It will include 30 men receiving sham TECAR therapy plus dietary and life style adjustments.

Evaluation Procedures:

1. Pain, voiding, and quality of life using the National Institutes of Health-Chronic Prostatitis Symptom Index.
2. Sleep quality using the Pittsburgh Sleep Quality Index.
3. Erectile function using the International Index of Erectile Function.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Saher Elgayar, Ph.D; Phone Number: +201020429911; Email: saherlotfy020@gmail.com
• Study Contact Backup: Name: Mohammed Elhamrawy, Ph.D

Study Locations

• Egypt
  • Tanta, Egypt
    • Tanta University Hospital
    • Contact: Mohamed Rady Ewis; Email: mohamedrady@yahoo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months.
• Ages will be ranged from 30 to 50 years old.

Exclusion Criteria:

1. Urinary and seminal infections.
2. Recent parenteral steroid administration.
3. Prior prostate or pelvic surgery.
4. Lower urinary tract disorders such as bladder stones.
5. Implanted electronic devices as pacemakers.
6. Sensory loss over the perineum.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: Control group	Device: Sham TECAR therapy; The procedure is similar to the active treatment of TECAR, but with the critical difference being that the output intensity of the TECAR device will be set to zero during the session.
Active Comparator: TECAR therapy group	Device: TECAR therapy; WINBACK 3SE (France) will be used for TECAR therapy in this study. To facilitate optimal distribution of endogenous heat therapy and effective contact between the active electrodes, both capacitive and resistive, and the surface of the skin, a layer of high-conductivity cream will be applied to the treatment region. The plate, an inactive electrode, which has a specific size (21cm*15cm), will be placed on the gluteal region. The capacitive electrode was employed for a duration of seven and a half minutes, at an intensity of 30-40%, whereas the resistance electrode will be utilized for an equivalent period over the perineum at the same intensity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pelvic pain	Pain will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index	Baseline and 8 weeks later

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life of men	Quality of life will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index	Baseline and after 8 weeks

Collaborators and Investigators

• Sponsor: Middle East University
• Investigators: Study Director: Mohammed Saif, National institute for Gerontology

Study record dates

Study Major Dates

• Study Start (Estimated): January 2, 2026
• Primary Completion (Estimated): April 1, 2026
• Study Completion (Estimated): April 7, 2026

Study Registration Dates

• First Submitted: December 23, 2025
• First Submitted That Met QC Criteria: December 23, 2025
• First Posted (Actual): January 7, 2026

Study Record Updates

• Last Update Posted (Actual): January 7, 2026
• Last Update Submitted That Met QC Criteria: December 23, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatitis
• Other Study ID Numbers: TECAR therapy

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No